NAFLD and NASH: The Metabolically Diseased Liver

脂肪性肝炎 医学 脂肪肝 胰岛素抵抗 肝活检 肝病 肝硬化 代谢综合征 脂肪变性 人口 内科学 纤维化 慢性肝病 胃肠病学 生物信息学 病理 疾病 肥胖 活检 生物 环境卫生
作者
Angelo Armandi,Jörn Markus Schattenberg
出处
期刊:Handbook of experimental pharmacology [Springer Science+Business Media]
卷期号:274: 253-267 被引量:15
标识
DOI:10.1007/164_2021_561
摘要

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease, with a global prevalence of approximately 24% in the general population. It is caused by fat accumulation in the liver secondary to insulin resistance, visceral obesity, and/or features of metabolic syndrome. A genetic susceptibility contributes to the phenotype, accounting for a more severe course of liver disease and the observed clinical variability. In fact, despite liver steatosis being considered a relatively benign entity, inflammation related to oxidative stress and lipid-derived damage may lead to non-alcoholic steatohepatitis (NASH), which constitutes the progressive disease. Accumulation of hepatic fibrosis can lead to cirrhosis and provide the environment for hepatocellular carcinoma. Obese and diabetic individuals represent a well-acknowledged high risk population. The assessment of liver fibrosis plays a crucial role in clinical setting, as liver-related mortality increases parallel to fibrosis stage. A liver biopsy is currently considered the reference standard for the diagnosis of NASH and the fibrosis stage, but many non-invasive tools are used with the aim of replacing histology for diagnosis and prognosis purposes. Blood based scores and liver stiffness are the most widely used and validated tools to assess liver fibrosis. Management of NAFLD resides on environmental interventions, including diet and physical activity to induce weight loss, and avoiding harmful nutrients, including fructose-sweetened beverages and high glycemic index foods, that are directly implied in liver injury. Multiple trials with investigational drugs are currently explored to treat fibrosing NASH, with promising results and it can be expected that a liver direct therapy aiming at steatohepatitis and fibrosis will become available soon.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
花样年华发布了新的文献求助10
刚刚
查查完成签到,获得积分10
1秒前
1秒前
Leti完成签到 ,获得积分10
1秒前
呍呢嗱完成签到,获得积分10
2秒前
xjh的应助被四季西瓜采纳,获得10
2秒前
2秒前
自由草莓发布了新的文献求助10
3秒前
3秒前
水鸟完成签到,获得积分10
3秒前
diana完成签到,获得积分10
4秒前
科研通AI6.3的应助被AGNOY采纳,获得10
4秒前
4秒前
烟花的应助被luoll采纳,获得10
4秒前
杨JY完成签到,获得积分10
5秒前
不同完成签到,获得积分10
5秒前
暴躁月亮完成签到 ,获得积分10
6秒前
6秒前
乎乎发布了新的文献求助10
6秒前
6秒前
DW的应助被白芷苏采纳,获得10
6秒前
彭于晏的应助被92567采纳,获得10
7秒前
顾矜的应助被rtzl采纳,获得10
7秒前
gg发布了新的文献求助10
7秒前
exile发布了新的文献求助10
7秒前
好吗好的完成签到,获得积分20
7秒前
Joy发布了新的文献求助10
7秒前
ldd完成签到,获得积分10
8秒前
哈哈完成签到 ,获得积分10
8秒前
EarholeDoctor完成签到,获得积分10
9秒前
钟梓袄发布了新的文献求助10
9秒前
188男神完成签到 ,获得积分10
10秒前
好吗好的发布了新的文献求助10
10秒前
Linus发布了新的文献求助10
10秒前
11秒前
所所的应助被ephemeral采纳,获得10
11秒前
12秒前
jiang发布了新的文献求助20
12秒前
彭于晏的应助被岩追研采纳,获得10
12秒前
大个的应助被清辉影采纳,获得30
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148